Bronstein, Gewirtz & Grossman LLC Urges Boston Scientific Investors to Act: Class Action Filed Alleging Investor Harm

Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announced that a class action lawsuit has been filed against Boston Scientific Corporation (NYSE: BSX) and certain of its officers.

The lawsuit seeks to recover damages for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Boston Scientific securities between July 23, 2025 and February 3, 2026, inclusive (the “Class Period”). Investors are encouraged to review the case materials at bgandg.com/BSX.

Boston Scientific case details

The complaint alleges that, during the Class Period, the defendants made materially false and misleading statements and/or failed to disclose that:

• Boston Scientific’s projected growth rate for fiscal year 2025—particularly within its U.S. electrophysiology (“EP”) segment—was not sustainable.
• Repeated statements expressing confidence in the U.S. EP division’s growth trajectory, competitive positioning, and contribution to overall net income lacked a reasonable basis.
• The company was experiencing material adverse trends affecting procedure volumes, increasing competitive pressures, and regulatory and reimbursement headwinds that were negatively impacting the U.S. EP segment.
• Management was aware that the U.S. EP segment was approaching a growth inflection point earlier than the market anticipated.
• As a result, positive statements regarding the sustainability of growth in key product segments and repeated upward revisions to full-year guidance were materially false and misleading.

What’s next for investors

A class action lawsuit has already been filed. A copy of the complaint is available at bgandg.com/BSX.

Investors who wish to request appointment as lead plaintiff must do so by May 4, 2026. The ability to share in any recovery does not require serving as lead plaintiff.

No cost to investors

Bronstein, Gewirtz & Grossman, LLC states that it represents investors in class actions on a contingency fee basis. The firm says it will ask the court to reimburse out-of-pocket expenses and attorneys’ fees—typically a percentage of total recovery—only if it is successful.

Firm statement

Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC, said: “Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”

Contact information

Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | info@bgandg.com

Attorney advertising. Prior results do not guarantee similar outcomes.